BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 29572582)

  • 21. Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome.
    Jothishankar B; Almazan T; Kim Y; Liauw S; Smith S; Kline J; Abdulla F
    Br J Haematol; 2019 Jul; 186(2):377-379. PubMed ID: 30937886
    [No Abstract]   [Full Text] [Related]  

  • 22. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of cutaneous lymphoma--current practice and future developments.
    Dummer R; Kempf W; Hess Schmid M; Häffner A; Burg G
    Onkologie; 2003 Aug; 26(4):366-72. PubMed ID: 12972705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
    Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous T-cell lymphoma.
    Lansigan F; Choi J; Foss FM
    Hematol Oncol Clin North Am; 2008 Oct; 22(5):979-96, x. PubMed ID: 18954747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy.
    Kuzel TM; Roenigk HH; Rosen ST
    J Clin Oncol; 1991 Jul; 9(7):1298-313. PubMed ID: 2045869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
    Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
    FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
    Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
    J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
    Hoppe RT; Wood GS; Abel EA
    Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
    Olsen EA; Rook AH; Zic J; Kim Y; Porcu P; Querfeld C; Wood G; Demierre MF; Pittelkow M; Wilson LD; Pinter-Brown L; Advani R; Parker S; Kim EJ; Junkins-Hopkins JM; Foss F; Cacchio P; Duvic M
    J Am Acad Dermatol; 2011 Feb; 64(2):352-404. PubMed ID: 21145619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of the primary cutaneous lymphomas.
    Prince HM; McCormack C; Ryan G; O'Keefe R; Seymour JF; Baker C
    Australas J Dermatol; 2003 Nov; 44(4):227-40; quiz 241-2. PubMed ID: 14616487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
    Thomas BR; Whittaker S
    Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycosis fungoides and Sézary syndrome - Review and outlook.
    Latzka J; Trautinger F
    J Dtsch Dermatol Ges; 2023 Apr; 21(4):386-391. PubMed ID: 36971307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I.
    Safai B
    Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870
    [No Abstract]   [Full Text] [Related]  

  • 39. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
    Sanches JA; Cury-Martins J; Abreu RM; Miyashiro D; Pereira J
    An Bras Dermatol; 2021; 96(4):458-471. PubMed ID: 34053802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.